Investigating how certain molecular features affect treatment response in advanced prostate cancer
Official title: Molecular features promoting sensitivity to LSD1i in castration-resistant prostate cancer
Funded at Johns Hopkins University · NIH-11043340 · Data updated 2026-11-12
This study is looking at why some advanced prostate cancers, especially neuroendocrine prostate cancer, respond better to a new treatment called LSD1 inhibitor, with the goal of finding ways to make treatments more effective for men facing this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $523,897 |
| NIH project number | 5R01CA279993-02 |
| Project ID | NIH-11043340 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer, particularly those with neuroendocrine features.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
What this research studies
This research focuses on understanding the molecular characteristics that make certain types of advanced prostate cancer, specifically neuroendocrine prostate cancer (NEPC), more sensitive to a new treatment called LSD1 inhibitor. By analyzing genetic and epigenetic features, the researchers aim to identify why NEPC responds better to this treatment compared to other prostate cancer subtypes. The study will utilize comprehensive genome-scale analyses and pharmacogenomics to develop a targeted approach that could improve treatment outcomes for patients. If successful, this could lead to more effective therapies for men suffering from this aggressive form of cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with advanced prostate cancer, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results with similar targeted therapies in other cancer types, indicating potential for success in this approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Brennen, William Nathaniel — Johns Hopkins University
- Study coordinator: Brennen, William Nathaniel
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.